Sandoz Zarxio Launch Still Faces Hurdles; ‘Chess Game’ With Amgen Continues

Federal Circuit ruling frees Sandoz to begin marketing first U.S. biosimilar after Sept. 2 but it still must overcome pending infringement suit and chance Amgen will assert more patents.